{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T00:23:12Z","timestamp":1794010992471,"version":"4.8.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T00:00:00Z","timestamp":1704412800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T00:00:00Z","timestamp":1704412800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Cancer Center Research and Development Fund","award":["29-A-3"],"award-info":[{"award-number":["29-A-3"]}]},{"name":"National Cancer Center Research and Development Fund","award":["2020-J-3"],"award-info":[{"award-number":["2020-J-3"]}]},{"name":"National Cancer Center Research and Development Fund","award":["2023-J-03"],"award-info":[{"award-number":["2023-J-03"]}]},{"DOI":"10.13039\/501100004206","name":"Osaka University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004206","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gastric Cancer"],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The prognosis for marginally resectable gastric cancer with extensive lymph node metastasis (ELM) remains unfavorable, even after R0 resection. To assess the safety and efficacy of preoperative docetaxel, oxaliplatin, and S-1 (DOS), we conducted a multicenter phase II trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Eligibility criteria included histologically proven HER2-negative gastric adenocarcinoma with bulky nodal (bulky N) involvement around major branched arteries or para-aortic node (PAN) metastases. Patients received three cycles of docetaxel (40\u00a0mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      , day 1), oxaliplatin (100\u00a0mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      , day 1), and S-1 (80\u2013120\u00a0mg\/body, days 1\u201314), followed by gastrectomy with D2 plus PAN dissection. Subsequently, patients underwent postoperative chemotherapy with S-1 for 1\u00a0year. The primary endpoint was major (grade\u2009\u2265\u20092a) pathological response rate (pRR) according to the Japanese Classification of Gastric Carcinoma criteria.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Between October 2018 and March 2022, 47 patients (bulky N, 20; PAN, 17; both, 10) were enrolled in the trial. One patient was ineligible. Another declined any protocol treatments before initiation. Among the 45 eligible patients who initiated DOS chemotherapy, 44 (98%) completed 3 cycles and 42 (93%) underwent R0 resection. Major pRR and pathological complete response rates among the 46 eligible patients, including the patient who declined treatment, were 57% (26\/46) and 24% (11\/46), respectively. Common grade 3 or 4 toxicities were neutropenia (24%), anorexia (16%), febrile neutropenia (9%), and diarrhea (9%). No treatment-related deaths occurred.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Preoperative chemotherapy with DOS yielded favorable pathological responses with an acceptable toxicity profile. This multimodal approach is highly promising for treating gastric cancer with ELM.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10120-023-01453-7","type":"journal-article","created":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T09:02:24Z","timestamp":1704445344000},"page":"366-374","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Short-term outcomes of preoperative chemotherapy with docetaxel, oxaliplatin, and S-1 for gastric cancer with extensive lymph node metastasis (JCOG1704)"],"prefix":"10.1007","volume":"27","author":[{"given":"Yukinori","family":"Kurokawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Doki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Kitabayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaki","family":"Yoshikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Nomura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunihiro","family":"Tsuji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruhiko","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Hihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Hiki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Souya","family":"Nunobe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junki","family":"Mizusawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narikazu","family":"Boku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Terashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,5]]},"reference":[{"key":"1453_CR1","unstructured":"International Agency for Research on Cancer. GLOBOCAN 2020. https:\/\/gco.iarc.fr\/today\/data\/factsheets\/cancers\/39-All-cancers-fact-sheet.pdf. Accessed August 17, 2023."},{"key":"1453_CR2","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1093\/bjs\/znac373","volume":"110","author":"Y Kurokawa","year":"2022","unstructured":"Kurokawa Y, Doki Y, Mizusawa J, et al. Five-year follow-up of a randomized clinical trial comparing bursectomy and omentectomy alone for resectable gastric cancer (JCOG1001). Br J Surg. 2022;110:50\u20136.","journal-title":"Br J Surg"},{"key":"1453_CR3","doi-asserted-by":"publisher","first-page":"40","DOI":"10.31662\/jmaj.2018-0006","volume":"1","author":"T Hashimoto","year":"2018","unstructured":"Hashimoto T, Kurokawa Y, Mori M, et al. Update on the treatment of gastric cancer. JMA Journal. 2018;1:40\u20139.","journal-title":"JMA Journal"},{"key":"1453_CR4","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1002\/ags3.12711","volume":"7","author":"Y Yanagimoto","year":"2023","unstructured":"Yanagimoto Y, Kurokawa Y, Doki Y. Essential updates 2021\/2022: perioperative and surgical treatments for gastric and esophagogastric junction cancer. Ann Gastroenterol Surg. 2023;7:698\u2013708.","journal-title":"Ann Gastroenterol Surg"},{"key":"1453_CR5","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1002\/bjs.6665","volume":"96","author":"T Yoshikawa","year":"2009","unstructured":"Yoshikawa T, Sasako M, Yamamoto S, et al. Phase II study of neoadjuvant chemotherapy and extended surgery for locally advanced gastric cancer. Br J Surg. 2009;96:1015\u201322.","journal-title":"Br J Surg"},{"key":"1453_CR6","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1002\/bjs.9484","volume":"101","author":"A Tsuburaya","year":"2014","unstructured":"Tsuburaya A, Mizusawa J, Tanaka Y, et al. Neoadjuvant chemotherapy with S-1 and cisplatin followed by D2 gastrectomy with para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis. Br J Surg. 2014;101:653\u201360.","journal-title":"Br J Surg"},{"key":"1453_CR7","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s10120-019-01007-w","volume":"23","author":"D Takahari","year":"2020","unstructured":"Takahari D, Ito S, Mizusawa J, et al. Long-term outcomes of preoperative docetaxel with cisplatin plus S-1 therapy for gastric cancer with extensive nodal metastasis (JCOG1002). Gastric Cancer. 2020;23:293\u20139.","journal-title":"Gastric Cancer"},{"key":"1453_CR8","doi-asserted-by":"crossref","unstructured":"Japanese Gastric Cancer Association. Japanese Gastric Cancer Treatment Guidelines 2021 (6th edition). Gastric Cancer. 2023;26:1\u201325.","DOI":"10.1007\/s10120-022-01331-8"},{"key":"1453_CR9","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1016\/S0140-6736(18)32557-1","volume":"393","author":"SE Al-Batran","year":"2019","unstructured":"Al-Batran SE, Homann N, Pauligk C, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2\/3 trial. Lancet. 2019;393:1948\u201357.","journal-title":"Lancet"},{"key":"1453_CR10","doi-asserted-by":"publisher","first-page":"2903","DOI":"10.1200\/JCO.20.02914","volume":"39","author":"Y-K Kang","year":"2021","unstructured":"Kang Y-K, Yook JH, Park Y-K, et al. PRODIGY: a phase III study of neoadjuvant docetaxel, oxaliplatin, and S-1 plus surgery and adjuvant S-1 versus surgery and adjuvant S-1 for resectable advanced gastric cancer. J Clin Oncol. 2021;39:2903\u201313.","journal-title":"J Clin Oncol"},{"key":"1453_CR11","doi-asserted-by":"crossref","unstructured":"Kang Y-K, Kim H-D, Yook JH, et al. Neoadjuvant docetaxel, oxaliplatin, and S-1 plus surgery and adjuvant S-1 for resectable advanced gastric cancer: final survival outcomes of the randomized phase 3 PRODIGY trial. J Clin Oncol. 2023;41(suppl 16; abstr 4067).","DOI":"10.1200\/JCO.2023.41.16_suppl.4067"},{"key":"1453_CR12","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1007\/s10120-022-01300-1","volume":"25","author":"T Saito","year":"2022","unstructured":"Saito T, Kurokawa Y, Takahashi T, et al. Neoadjuvant docetaxel, oxaliplatin and S-1 (DOS) combination chemotherapy for patients with resectable adenocarcinoma of esophagogastric junction. Gastric Cancer. 2022;25:966\u201372.","journal-title":"Gastric Cancer"},{"key":"1453_CR13","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1002\/ags3.12632","volume":"7","author":"Y Kurokawa","year":"2023","unstructured":"Kurokawa Y, Kawase T, Takeno A, et al. Phase 2 trial of neoadjuvant docetaxel, oxaliplatin, and S-1 for clinical stage III gastric or esophagogastric junction adenocarcinoma. Ann Gastroenterol Surg. 2023;7:247\u201354.","journal-title":"Ann Gastroenterol Surg"},{"key":"1453_CR14","doi-asserted-by":"publisher","first-page":"31","DOI":"10.2217\/fon-2019-0528","volume":"16","author":"Y Sato","year":"2020","unstructured":"Sato Y, Kurokawa Y, Doki Y, et al. A phase II study of preoperative chemotherapy with DOS in gastric cancer with extensive lymph node metastasis (JCOG1704). Future Oncol. 2020;16:31\u20138.","journal-title":"Future Oncol"},{"key":"1453_CR15","doi-asserted-by":"publisher","first-page":"2767","DOI":"10.1200\/JCO.2004.10.184","volume":"22","author":"T Sano","year":"2004","unstructured":"Sano T, Sasako M, Yamamoto S, et al. Gastric cancer surgery: morbidity and mortality results from a prospective randomized controlled trial comparing D2 and extended para-aortic lymphadenectomy\u2014Japan Clinical Oncology Group study 9501. J Clin Oncol. 2004;22:2767\u201373.","journal-title":"J Clin Oncol"},{"key":"1453_CR16","doi-asserted-by":"crossref","unstructured":"Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer. 2011;14:101\u2013112.","DOI":"10.1007\/s10120-011-0041-5"},{"key":"1453_CR17","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1002\/cncr.11660","volume":"98","author":"K Becker","year":"2003","unstructured":"Becker K, Mueller JD, Schulmacher C, et al. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer. 2003;98:1521\u201330.","journal-title":"Cancer"},{"key":"1453_CR18","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","volume":"240","author":"D Dindo","year":"2004","unstructured":"Dindo D, Demartines N, Clavien P-A. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205\u201313.","journal-title":"Ann Surg"},{"key":"1453_CR19","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1007\/s00595-015-1236-x","volume":"46","author":"H Katayama","year":"2016","unstructured":"Katayama H, Kurokawa Y, Nakamura K, et al. Extended Clavien\u2013Dindo classification of surgical complications: Japan Clinical Oncology Group postoperative complications criteria. Surg Today. 2016;46:668\u201385.","journal-title":"Surg Today"},{"key":"1453_CR20","unstructured":"Green S, Benedetti J, Crowley J. The design of clinical trials. In: Clinical trials in oncology, 2nd ed. Boca Raton: Chapman & Hall\/CRC; 2003. p. 41\u201377."},{"key":"1453_CR21","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1093\/annonc\/mdu472","volume":"26","author":"Y Yamada","year":"2015","unstructured":"Yamada Y, Higuchi K, Nishikawa K, et al. Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-na\u00efve patients with advanced gastric cancer. Ann Oncol. 2015;26:141\u20138.","journal-title":"Ann Oncol"},{"key":"1453_CR22","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1016\/S1470-2045(16)30531-9","volume":"17","author":"SE Al-Batran","year":"2016","unstructured":"Al-Batran SE, Hofheinz RD, Pauligk C, et al. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2\/3 trial. Lancet Oncol. 2016;17:1697\u2013708.","journal-title":"Lancet Oncol"},{"key":"1453_CR23","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1016\/S1470-2045(09)70259-1","volume":"10","author":"N Boku","year":"2009","unstructured":"Boku N, Yamamoto S, Fukuda H, et al. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol. 2009;10:1063\u20139.","journal-title":"Lancet Oncol"},{"key":"1453_CR24","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1007\/s10120-013-0294-2","volume":"17","author":"Y Kurokawa","year":"2014","unstructured":"Kurokawa Y, Shibata T, Sasako M, et al. Validity of response assessment criteria in neoadjuvant chemotherapy for gastric cancer (JCOG0507-A). Gastric Cancer. 2014;17:514\u201321.","journal-title":"Gastric Cancer"},{"key":"1453_CR25","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/s10120-014-0401-z","volume":"18","author":"K Nakamura","year":"2015","unstructured":"Nakamura K, Kuwata T, Shimoda T, et al. Determination of the optimal cutoff percentage of residual tumors to define the pathological response rate for gastric cancer treated with preoperative therapy (JCOG1004-A). Gastric Cancer. 2015;18:597\u2013604.","journal-title":"Gastric Cancer"},{"key":"1453_CR26","doi-asserted-by":"publisher","first-page":"3750","DOI":"10.1200\/JCO.22.00380","volume":"40","author":"RD Hofheinz","year":"2022","unstructured":"Hofheinz RD, Merx K, Haag GM, et al. FLOT versus FLOT\/trastuzumab\/pertuzumab perioperative therapy of human epidermal growth factor receptor 2-positive resectable esophagogastric adenocarcinoma: a randomized phase II trial of the AIO EGA Study Group. J Clin Oncol. 2022;40:3750\u201361.","journal-title":"J Clin Oncol"}],"container-title":["Gastric Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10120-023-01453-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10120-023-01453-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10120-023-01453-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,26]],"date-time":"2024-02-26T12:06:57Z","timestamp":1708949217000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10120-023-01453-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,5]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["1453"],"URL":"https:\/\/doi.org\/10.1007\/s10120-023-01453-7","relation":{},"ISSN":["1436-3291","1436-3305"],"issn-type":[{"value":"1436-3291","type":"print"},{"value":"1436-3305","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,5]]},"assertion":[{"value":"8 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Yukinori Kurokawa and Yuichiro Doki have received research funding and lecture fees from Taiho Pharmaceutical, Ono Pharmaceutical, Yakult Honsha, Eli Lilly Japan, and Daiichi Sankyo outside of the submitted work. Haruhiko Cho has received lecture fees from Yakult Honsha outside of the submitted work. Junki Mizusawa has received lecture fees from Taiho Pharmaceutical outside the submitted work; His spouse an employee of Pfizer. Narikazu Boku has received research funding from Ono Pharmaceutical and Takeda Pharmaceutical and lecture fees from Taiho Pharmaceutical, Ono Pharmaceutical, Bristol Myers Squib Japan, Eli Lilly Japan, and Daiichi Sankyo outside of the submitted work. Masanori Terashima has received personal fees from Taiho Pharmaceutical, Chugai Pharmaceutical, Ono Pharmaceutical, Bristol Myers Squib Japan, Yakult Honsha, Takeda Pharmaceutical, Eli Lilly Japan, Pfizer Japan, Daiichi Sankyo, Johnson and Johnson, Medtronic Japan, Intuitive Japan, and Olympus outside of the submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the Japanese Clinical Trials Act and the related regulations and with the 1964 Helsinki Declaration and its later amendments. Informed consent to be included in the study was obtained from all patients.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}}]}}